During our in vitro observations that MM cells carrying the del(8)(p21) responded poorly to bortezomib or bortezomib mediated sensitization to TRAIL/APO2L killing, we sought to investigate whether this phenomenon showed any effect in the clinical response of patients carrying the deletion. The gene discussed is TNFSF10; the disease is Miyoshi myopathy.